Targeting α-synuclein as a therapeutic strategy for Parkinsons disease

Nada B. Lawand, Nayef E. Saadé, Omar Ali El-Agnaf, Bared Safieh-Garabedian

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Introduction: α-Synuclein, a neuronal protein, plays a central role in the pathophysiology of Parkinsons disease (PD), the second most prevalent neurodegenerative disorder. Cases of PD have increased tremendously over the past decade necessitating the identification of new therapeutic targets to reduce patient morbidity and to improve PD patients quality of life.Areas covered: The purpose of this article is to provide an update on the role of α-synuclein in fibrils formation and review its role as an effective immunotherapeutic target for PD. The rapidly expanding evidence for the contribution of α-synuclein to the pathogenesis of PD led to the development of antibodies against the C terminus of α-synuclein and other molecules involved in the inflammatory signaling pathways that were found to contribute significantly to initiation and progression of the disease.Expert opinion: The readers will obtain new insights on the mechanisms by which α-synuclein can trigger the development of PD and other related degenerative disorders along with the potential role of active and passive antibodies targeted against specific form of α-synuclein aggregates to clear neurotoxicity, stop the propagation of the prion-like behavior of these oligomers and reverse neuronal degeneration associated with PD.

Original languageEnglish
Pages (from-to)1351-1360
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Volume19
Issue number10
DOIs
Publication statusPublished - 3 Oct 2015

Fingerprint

Synucleins
Parkinson Disease
Therapeutics
Antibodies
Prions
Expert Testimony
Neurodegenerative Diseases
Disease Progression
Oligomers
Quality of Life
Morbidity

Keywords

  • immunotherapy
  • inflammation
  • Lewy bodies
  • neurodegenerative disorder
  • Parkinson's disease
  • synucleinopathies
  • α-synuclein

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Targeting α-synuclein as a therapeutic strategy for Parkinsons disease. / Lawand, Nada B.; Saadé, Nayef E.; Ali El-Agnaf, Omar; Safieh-Garabedian, Bared.

In: Expert Opinion on Therapeutic Targets, Vol. 19, No. 10, 03.10.2015, p. 1351-1360.

Research output: Contribution to journalReview article

Lawand, Nada B. ; Saadé, Nayef E. ; Ali El-Agnaf, Omar ; Safieh-Garabedian, Bared. / Targeting α-synuclein as a therapeutic strategy for Parkinsons disease. In: Expert Opinion on Therapeutic Targets. 2015 ; Vol. 19, No. 10. pp. 1351-1360.
@article{708bd924ccc04fecb5294a849c720f1b,
title = "Targeting α-synuclein as a therapeutic strategy for Parkinsons disease",
abstract = "Introduction: α-Synuclein, a neuronal protein, plays a central role in the pathophysiology of Parkinsons disease (PD), the second most prevalent neurodegenerative disorder. Cases of PD have increased tremendously over the past decade necessitating the identification of new therapeutic targets to reduce patient morbidity and to improve PD patients quality of life.Areas covered: The purpose of this article is to provide an update on the role of α-synuclein in fibrils formation and review its role as an effective immunotherapeutic target for PD. The rapidly expanding evidence for the contribution of α-synuclein to the pathogenesis of PD led to the development of antibodies against the C terminus of α-synuclein and other molecules involved in the inflammatory signaling pathways that were found to contribute significantly to initiation and progression of the disease.Expert opinion: The readers will obtain new insights on the mechanisms by which α-synuclein can trigger the development of PD and other related degenerative disorders along with the potential role of active and passive antibodies targeted against specific form of α-synuclein aggregates to clear neurotoxicity, stop the propagation of the prion-like behavior of these oligomers and reverse neuronal degeneration associated with PD.",
keywords = "immunotherapy, inflammation, Lewy bodies, neurodegenerative disorder, Parkinson's disease, synucleinopathies, α-synuclein",
author = "Lawand, {Nada B.} and Saad{\'e}, {Nayef E.} and {Ali El-Agnaf}, Omar and Bared Safieh-Garabedian",
year = "2015",
month = "10",
day = "3",
doi = "10.1517/14728222.2015.1062877",
language = "English",
volume = "19",
pages = "1351--1360",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Targeting α-synuclein as a therapeutic strategy for Parkinsons disease

AU - Lawand, Nada B.

AU - Saadé, Nayef E.

AU - Ali El-Agnaf, Omar

AU - Safieh-Garabedian, Bared

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Introduction: α-Synuclein, a neuronal protein, plays a central role in the pathophysiology of Parkinsons disease (PD), the second most prevalent neurodegenerative disorder. Cases of PD have increased tremendously over the past decade necessitating the identification of new therapeutic targets to reduce patient morbidity and to improve PD patients quality of life.Areas covered: The purpose of this article is to provide an update on the role of α-synuclein in fibrils formation and review its role as an effective immunotherapeutic target for PD. The rapidly expanding evidence for the contribution of α-synuclein to the pathogenesis of PD led to the development of antibodies against the C terminus of α-synuclein and other molecules involved in the inflammatory signaling pathways that were found to contribute significantly to initiation and progression of the disease.Expert opinion: The readers will obtain new insights on the mechanisms by which α-synuclein can trigger the development of PD and other related degenerative disorders along with the potential role of active and passive antibodies targeted against specific form of α-synuclein aggregates to clear neurotoxicity, stop the propagation of the prion-like behavior of these oligomers and reverse neuronal degeneration associated with PD.

AB - Introduction: α-Synuclein, a neuronal protein, plays a central role in the pathophysiology of Parkinsons disease (PD), the second most prevalent neurodegenerative disorder. Cases of PD have increased tremendously over the past decade necessitating the identification of new therapeutic targets to reduce patient morbidity and to improve PD patients quality of life.Areas covered: The purpose of this article is to provide an update on the role of α-synuclein in fibrils formation and review its role as an effective immunotherapeutic target for PD. The rapidly expanding evidence for the contribution of α-synuclein to the pathogenesis of PD led to the development of antibodies against the C terminus of α-synuclein and other molecules involved in the inflammatory signaling pathways that were found to contribute significantly to initiation and progression of the disease.Expert opinion: The readers will obtain new insights on the mechanisms by which α-synuclein can trigger the development of PD and other related degenerative disorders along with the potential role of active and passive antibodies targeted against specific form of α-synuclein aggregates to clear neurotoxicity, stop the propagation of the prion-like behavior of these oligomers and reverse neuronal degeneration associated with PD.

KW - immunotherapy

KW - inflammation

KW - Lewy bodies

KW - neurodegenerative disorder

KW - Parkinson's disease

KW - synucleinopathies

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=84941798927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941798927&partnerID=8YFLogxK

U2 - 10.1517/14728222.2015.1062877

DO - 10.1517/14728222.2015.1062877

M3 - Review article

C2 - 26135549

AN - SCOPUS:84941798927

VL - 19

SP - 1351

EP - 1360

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 10

ER -